Journal ArticleDOI
Targeting public neoantigens for cancer immunotherapy.
Alexander H. Pearlman,Alexander H. Pearlman,Michael S. Hwang,Maximilian F. Konig,Emily Han-Chung Hsiue,Emily Han-Chung Hsiue,Jacqueline Douglass,Jacqueline Douglass,Sarah R. DiNapoli,Sarah R. DiNapoli,Brian J. Mog,Chetan Bettegowda,Drew M. Pardoll,Sandra B. Gabelli,Nicholas Papadopoulos,Kenneth W. Kinzler,Bert Vogelstein,Shibin Zhou +17 more
- Vol. 2, Iss: 5, pp 487-497
TLDR
The opportunities and challenges involved in the identification of suitable public neoantigen targets and the development of therapeutic agents targeting them are reviewed.Abstract:
Several current immunotherapy approaches target private neoantigens derived from mutations that are unique to individual patients’ tumors. However, immunotherapeutic agents can also be developed against public neoantigens derived from recurrent mutations in cancer driver genes. The latter approaches target proteins that are indispensable for tumor growth, and each therapeutic agent can be applied to numerous patients. Here we review the opportunities and challenges involved in the identification of suitable public neoantigen targets and the development of therapeutic agents targeting them. Zhou and colleagues discuss the opportunities and challenges in targeting public neoantigens for cancer immunotherapy.read more
Citations
More filters
Journal ArticleDOI
Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs
Mark Yarmarkovich,Quinlen F. Marshall,John M. Warrington,Rasika Premaratne,Alvin Farrel,David Groff,Wei Li,Moreno Di Marco,Erin Runbeck,Hau Truong,Jugmohit S. Toor,Sarvind Tripathi,Son Nguyen,Helena Shen,Tiffany Noel,Nicole L. Church,Amber K. Weiner,Nathan M. Kendsersky,Daniel Martinez,Rebecca Weisberg,Molly Christie,Laurence C. Eisenlohr,Kristopher R. Bosse,Kristopher R. Bosse,Dimiter S. Dimitrov,Stefan Stevanovic,Nikolaos G. Sgourakis,Ben R. Kiefel,John M. Maris,John M. Maris +29 more
TL;DR: In this article, a peptide-centric chimeric antigen receptor (CAR) was proposed to target unmutated peptide QYNPIRTTF, discovered on HLA-A*24:02, derived from the neuroblastoma dependency gene and master transcriptional regulator PHOX2B.
Journal ArticleDOI
Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
TL;DR: The differing mechanisms of T cell antigen recognition and signal transduction mediated through CARs and TCRs are described and both classical and emerging pre-clinical strategies for antigen-specific TCR discovery, enhancement, and validation are discussed.
Journal ArticleDOI
Neoantigens: promising targets for cancer therapy
TL;DR: Neoantigens are newly formed antigens generated by tumor cells as a result of various tumor-specific alterations, such as genomic mutation, dysregulated RNA splicing, disordered post-translational modification, and integrated viral open reading frames as mentioned in this paper .
Journal ArticleDOI
Thermal immuno-nanomedicine in cancer
Zhe Yang,Di Gao,Jing Zhao,Gaojie Yang,Mingli Guo,Yiming Wang,Xuechun Ren,Jong Seung Kim,L. Jin,Zhongmin Tian,Jing Zhang +10 more
Journal ArticleDOI
Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic
TL;DR: In this review, Bewersdorf and Abdel-Wahab discuss the development of promising new molecular targeted approaches for AML, including menin inhibition, novel IDH1/2 inhibitors, and preclinical means to target TET2, ASXL1, and RNA splicing factor mutations.
References
More filters
Journal ArticleDOI
Understanding the Spatial Topology of Artificial Immunological Synapses Assembled in T Cell-Redirecting Strategies: A Major Issue in Cancer Immunotherapy
TL;DR: By connecting CD3 signaling molecules with a recognition process independent of the TCR variable domains, T cells can be hot-wired to recognize a user-defined cell-surface TAA that is not associated with the major histocompatibility complex (MHC) to activate effector cell responses and kill cancer cells.
Journal ArticleDOI
Rapid Identification and Evaluation of Neoantigen-reactive T-Cell Receptors From Single Cells.
Biman C. Paria,Noam Levin,Frank J. Lowery,Anna Pasetto,Drew C. Deniger,Maria R. Parkhurst,Rami Yossef,Sang-hyun Kim,Maria Florentin,Lien T. Ngo,Satyajit Ray,Sri Krishna,Paul F. Robbins,Steven A. Rosenberg +13 more
TL;DR: Development of a unique demultiplexing method for identification of TCRα, adaptation of synthetic TCRs for gene transfer, and a reliable reporter system significantly shortens TCR discovery time over conventional methods and increases throughput to facilitate testing prospective personalized T CRs for adoptive cell therapy.
Journal ArticleDOI
Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine
TL;DR: The multipeptide KRAS vaccine was immunogenic and efficacious in the primary prevention ofKRAS-induced lung cancer, indicating that the approach potentially can be used to prevent other KRAS-driven cancers, either alone or in combination with other modalities.
Journal ArticleDOI
Solving an MHC allele-specific bias in the reported immunopeptidome.
Martin G. Klatt,Kyeara N. Mack,Yang Bai,Zita E.H. Aretz,Zita E.H. Aretz,Levy I Nathan,Sung Soo Mun,Tao Dao,David A. Scheinberg +8 more
TL;DR: Higher concentrations of acetonitrile increased overall MHC ligand identifications by 2-fold, increased detection of cancer germline antigen–derived peptides by 50%, and resulted in profound variations in isolation efficacy between different MHC alleles correlated with the hydrophobicity of their anchor residues.
Journal ArticleDOI
A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.
TL;DR: Results suggest WT1:126-134 may not be a suitable target for T-cell based tumor immunotherapies and suggest antigen processing defects in some leukemias.